Print Page   |   Contact Us   |   Sign In   |   Join
News and Press: Member Organization News

Armune BioScience Expands Access to Apifiny with Accu Reference Medical Lab

Wednesday, January 20, 2016   (0 Comments)
Posted by: Kate Oesterle
Share |

Kalamazoo, MI (PRWEB) January 19, 2016

Armune BioScience signed a definitive agreement with Accu Reference Medical Laboratory to offer Apifiny® to their rapidly growing physician account base in over 15 states. Launched in April of 2015, Apifiny is the only cancer specific, non-PSA blood test designed to aid clinicians in the detection of prostate cancer. Apifiny order volume exceeded 3,000 tests in 2015. Primary care physicians and urologists have utilized Apifiny to help move beyond PSA based testing to assess prostate cancer risk.

Armune BioScience, Inc. is a Michigan-based life sciences company that developed Apifiny. Apifiny was developed based on innovative research into the immune system’s response to cancer conducted at the University of Michigan. Armune is currently expanding testing throughout the United States and preparing to expand into several markets worldwide in the coming months.

Read More.

Creating Value
by delivering business-critical resources & bottom line savings
Building Networks
by connecting Michigan's bio-industry one member at a time
Growing Talent
by creating opportunities that develop people & build organizations
Membership Software Powered by®  ::  Legal